

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6853536

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CRYSTALLICS B.V.	04/24/2018
RECEIVING PARTY DATA	
Name:	VENATORX PHARMACEUTICALS, INC.
Street Address:	30 SPRING MILL DRIVE
City:	MALVERN
State/Country:	PENNSYLVANIA
Postal Code:	19355
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17353377
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 493-9300
Email:	melissa.sanchez@wsgr.com, patentdocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	41223-723.401
NAME OF SUBMITTER:	MELISSA SANCHEZ
SIGNATURE:	/Melissa Sanchez/
DATE SIGNED:	08/03/2021
Total Attachments: 2	
source=VenatoRx 41223-723.401 Executed PCT Assignment (Crystallics to VenatoRx) 4814-8373-6820 v.1#page1.tif	
source=VenatoRx 41223-723.401 Executed PCT Assignment (Crystallics to VenatoRx) 4814-8373-6820 v.1#page2.tif	

WHEREAS, CRYSTALLICS B.V. (hereinafter "Assignor"), the assignee of an interest in the entirety of the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

**SOLID FORMS AND COMBINATION COMPOSITIONS COMPRISING
A BETA-LACTAMASE INHIBITOR AND USES THEREOF**

for which a PCT application serial number PCT/US2018/020968 was filed on March 5, 2018 in the United States Receiving Office of the Patent Cooperation Treaty;

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, VENATORX PHARMACEUTICALS, INC., a corporation incorporated in the State of Delaware, having a place of business at 30 Spring Mill Drive, Malvern, PA 19355, USA, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 41223-723.601


ASSIGNOR: CRYSTALLICS B.V.

Date: April 24, 2018

By: 

Name: M. HOFFMANN
Title: Scientific Director

Witness:



ANA FERNANDEZ

(printed name)

Witness:



GIOVANNA BRANCATELLI

(printed name)

Date: 24 APRIL 2018

Date: 24 April 2018

Address:

MEIJERGR. DREEF 31
1105 A2 AMSTERDAM

Address:

MEIJERGR. DREEF 31
1105 A2 AMSTERDAM

RECEIVED AND AGREED TO BY ASSIGNEE: VENATORX PHARMACEUTICALS, INC.

Date: 30 April 18

By: 

Name: Christopher J. Burns, Ph.D
Title: Resident and Chief Scientific Officer